Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE). At the end of 2017, the FDA approved the registration of Novartis Europharm ‘ Omalizumab, which will enter the field of anti-COPD and moderate to severe persistent allergic asthma. Since then, Omalizumab has been officially launched in China. Omalizumab is the only monoclonal antibody currently on the market in China for the treatment of asthma. By the first half of 2021, Novartis Europharm is the only manufacturer in the Chinese Omalizumab market.
According to CRI’s market research, Omalizumab sales have increased year by year from 2018 to 2020. At the beginning of 2020, Omalizumab was included in China’s medical insurance as a treatment for respiratory diseases. During the period of the COVID-19 epidemic, the sales of Omalizumab has increased. Therefore, its sales value reached CNY41.61 million in China in 2020, with an annual growth rate of 281.5%. The CAGR of Omalizumab’s sales value in the Chinese market from 2018 to 2020 is 163.2%.
CRI predicts that with the increase in the number of indications, the sales of Omalizumab in China will continue to grow from 2021 to 2025. China is one of the countries with the highest mortality rate of asthma in the world. In 2020, there were about 30 million asthma patients in China, which was 1.5 times higher than the number of patients in 2017 (20 million). Therefore, it can be speculated that the number of indications of Omalizumab in China will continue to grow and sales will increase accordingly. Omalizumab is clinically more accurate and more effective than inhaled corticosteroids and long-acting inhaled β2-adrenergic receptor agonists, especially for patients with moderate to severe asthma. Based on these therapeutic advantages, the market share of Omalizumab will increase in the future. In addition, Omalizumab has only been approved for one indication in China, and 4 indications have been approved globally. Therefore, the number of approved indications for Omalizumab in China still has potential for growth. It can be predicted that its sales will continue to grow with the expansion of the market and the increase of the number of indications in the future.
-The impact of COVID-19 on China’s Omalizumab market
– Sales value of China’s Omalizumab 2016-2020
– Competitive landscape of China’s Omalizumab market
– Prices of Omalizumab in China
– Prices of Omalizumab in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Omalizumab market
– Prospect of China’s Omalizumab market from 2021 to 2025